蛋白酶体抑制剂PS-341在恶性血液病中的研究现状
摘要
蛋白酶体抑制剂PS-341通过抑制蛋白酶体及NF-κB等机制使肿瘤细胞凋亡,在多发性骨髓瘤等恶性血液病的治疗方而取得了一定的进展。本文就PS-341在恶性血液病中的作用机制、临床疗效及毒副作用作一综述。
出处
《国外医学（输血及血液学分册）》
2004年第4期329-332,共4页
Foreign Medical Sciences(Section of Blood Transfusion and Heanatology)
参考文献25
-
1An WG, Hwang SG, Trepel JB, et al. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIPI, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia, 2000,14(7): 1276-1283.
-
2Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents:therapeutic applications. Blood, 2003,101 (6) :2377-2380.
-
3Richardson PG, Berenson J, Irwin D, et al. Phase Ⅱ study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most
-
4Julian A. Development of the Proteasome Inhibitor PS-341. The Oncologist, 2002,7: 9-16.
-
5Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol, 2001,28(6):613-619.
-
6Orlowski RZ, Stinchcombe TE, Mitchell BS. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol, 2002, 20 (22): 4420-4427.
-
7Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents.Cancer Res, 1999,59(11) :2615-2622.
-
8Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res, 2002,62(4):1083-1086.
-
9Chandra J, Niemer I, Gilbereath J,et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant Chronic Lymphocytic Leukemic Lymphocytes. Blood, 1998, 92(11):4220-4229.
-
10Orlowski RZ, Eswara JR, Lafond-Walker A, et al. Tumor growth inhibitor induced in a murine model of human Burkitt's Lymphoma by a proteasome inhibitor. Cancer Res, 1998, 58:4342-4348.
-
1丁晔.蛋白酶体抑制剂PS—34——治疗骨髓瘤的新方法[J].国外医学（输血及血液学分册）,2002,25(5):405-407. 被引量：1
-
2林如峰,陆化,刘澎,王永韧,沈文怡,费小明,葛峥,汪承亚.蛋白酶体抑制剂PS-341对U266细胞凋亡和多种细胞因子表达影响的研究[J].南京医科大学学报（自然科学版）,2007,27(3):220-223.
-
3林如峰,陆化,刘澎,沈文怡,张建富,吴雨洁,费小明,李建勇.蛋白酶体抑制剂PS-341对多发性骨髓瘤骨髓间充质干细胞多种细胞因子表达的影响[J].中国实验血液学杂志,2006,14(1):61-64. 被引量：7
-
4黄建新,牧启田,卓志红,楼燕如,张怡,欧阳桂芳,陆滢.蛋白酶体抑制剂PS-341对白血病细胞株SHI-1的生长抑制作用研究[J].浙江医学,2008,30(7):694-695.
-
5罗绍凯.恶性血液病的治疗现状[J].新医学,1999,30(11):623-624. 被引量：3
-
6孙鹏,林凤茹,李改英,颜晓燕.AF1q基因在白血病患者中的表达及临床意义[J].中华血液学杂志,2008,29(8):559-560.
-
7孙鹏,林凤茹.AF1q基因在恶性血液病中的表达及其预后意义[J].白血病．淋巴瘤,2007,16(4):311-313.
-
8林如峰,陆化,沈文怡,刘澎,王永韧,汪承亚,李建勇.蛋白酶体抑制剂PS-341对多发性骨髓瘤间充质干细胞IL-1β表达的影响[J].江苏医药,2006,32(4):337-339. 被引量：3
-
9林如峰,陆化,刘澎,王永韧,沈文怡,吴雨洁,张建富,葛峥,汪承亚,李建勇.蛋白酶体抑制剂PS-341诱导U266细胞凋亡与胞浆内[Ca^(2+)]变化的关系[J].肿瘤防治研究,2007,34(11):822-824. 被引量：1
-
10肖洁,尹松梅.血管内皮生长因子与恶性血液病的治疗[J].广东医学,2007,28(6):1006-1008. 被引量：1
